Skip to content

PROPANC BIOPHARMA, INC.: 10-Q filed 2026-05-14

What PROPANC BIOPHARMA, INC. reported in its quarterly report filed 2026-05-14 (fiscal Q3 2026): 40 published measures, 117 facts as tagged in accession 0001493152-26-023210.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-14
Fiscal period
fiscal Q3 2026
Accession
0001493152-26-023210 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROPANC BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-3114,333,780USD
At 2025-06-3019,631,808USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-03-313,505,895USD
At 2025-06-305,725,616USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-319,827,885USD
At 2025-12-3110,452,265USD
At 2025-09-3014,361,167USD
At 2025-06-3013,906,192USD
At 2025-03-3118,092,292USD
At 2024-12-31-4,158,759USD
At 2024-09-30-4,108,085USD
At 2024-06-30-3,779,059USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-6,360,336USD90
2025-07-01 to 2026-03-31-14,289,468USD274
2025-10-01 to 2025-12-31-3,091,394USD92
2025-07-01 to 2025-09-30-4,837,738USD92
2025-01-01 to 2025-03-31-54,067,346USD90
2024-07-01 to 2025-03-31-54,851,839USD274
2024-10-01 to 2024-12-31-430,183USD92
2024-07-01 to 2024-09-30-354,310USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-07-01 to 2026-03-31-4,080,653USD274
2024-07-01 to 2025-03-31-312,982USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-07-01 to 2026-03-314,912USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-07-01 to 2026-03-314,473,485USD274
2024-07-01 to 2025-03-31418,000USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-07-01 to 2026-03-31-4,912USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-140,843,234USD
At 2025-06-30-125,621,520USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-01-01 to 2026-03-3122,427,486shares90
2025-07-01 to 2026-03-3115,973,535shares274
2025-01-01 to 2025-03-314,325,994shares90
2024-07-01 to 2025-03-311,420,307shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-3122,427,486shares90
2025-07-01 to 2026-03-3115,973,535shares274
2025-01-01 to 2025-03-314,325,994shares90
2024-07-01 to 2025-03-311,420,307shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.28USD/shares90
2025-07-01 to 2026-03-31-0.95USD/shares274
2025-01-01 to 2025-03-31-12.5USD/shares90
2024-07-01 to 2025-03-31-38.62USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-0.28USD/shares90
2025-07-01 to 2026-03-31-0.95USD/shares274
2025-01-01 to 2025-03-31-12.5USD/shares90
2024-07-01 to 2025-03-31-38.62USD/shares274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-03-314,221USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-07-01 to 2026-03-317,270,003USD274
2024-07-01 to 2025-03-311,505,115USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-6,400,221USD90
2025-07-01 to 2026-03-31-14,728,519USD274
2025-01-01 to 2025-03-31-53,128,713USD90
2024-07-01 to 2025-03-31-53,632,885USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-318,223,488USD
At 2025-06-308,352,816USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-313,475,628USD
At 2025-06-305,578,240USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-03-31973,692USD
At 2025-06-301,249,596USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-01-01 to 2026-03-316,400,221USD90
2025-07-01 to 2026-03-3114,728,519USD274
2025-01-01 to 2025-03-3153,128,713USD90
2024-07-01 to 2025-03-3153,632,885USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-01-01 to 2026-03-31169,660USD90
2025-07-01 to 2026-03-31249,822USD274
2025-01-01 to 2025-03-3154,097USD90
2024-07-01 to 2025-03-31170,199USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-03-3121,859,281shares
At 2025-06-3011,611,782shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-31149,427,962USD
At 2025-06-30138,243,652USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-03-311,234,766USD
At 2025-06-301,318,917USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-03-3146,584USD
At 2025-06-3059,413USD
At 2025-05-0462,126USD
At 2022-05-0466,201USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-05-0462,126USD
At 2022-05-0466,201USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2026-03-3155,000USD
At 2025-06-30537,921USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2026-03-3131,181USD
At 2025-06-3025,078USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2026-03-3126,960USD
At 2025-06-3025,078USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-6,360,336USD90
2025-07-01 to 2026-03-31-14,289,468USD274
2025-01-01 to 2025-03-31-54,067,346USD90
2024-07-01 to 2025-03-31-54,851,839USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-6,453,685USD90
2025-07-01 to 2026-03-31-15,305,865USD274
2025-01-01 to 2025-03-31-54,094,657USD90
2024-07-01 to 2025-03-31-54,656,863USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-6,360,336USD90
2025-07-01 to 2026-03-31-15,221,714USD274
2025-01-01 to 2025-03-31-54,067,346USD90
2024-07-01 to 2025-03-31-54,851,839USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-316,219,644USD90
2025-07-01 to 2026-03-3114,446,391USD274
2025-01-01 to 2025-03-3153,068,147USD90
2024-07-01 to 2025-03-3153,442,499USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2026-01-01 to 2026-03-31316USD90
2025-07-01 to 2026-03-31670USD274
2025-01-01 to 2025-03-310USD90

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2026-01-01 to 2026-03-3138,270USD90
2025-07-01 to 2026-03-31402,874USD274
2025-01-01 to 2025-03-31104,042USD90
2024-07-01 to 2025-03-31309,215USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-01-01 to 2026-03-3143,000USD90
2025-07-01 to 2026-03-31-11,000USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-01-01 to 2026-03-3139,885USD90
2025-07-01 to 2026-03-31439,051USD274
2025-01-01 to 2025-03-31-938,633USD90
2024-07-01 to 2025-03-31-1,218,954USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-07-01 to 2026-03-31126,855USD274
2024-07-01 to 2025-03-3121,625USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-07-01 to 2026-03-313,314,458USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-07-01 to 2026-03-31-335,235USD274
2024-07-01 to 2025-03-31118,706USD274

Inspect the source

Entity
PROPANC BIOPHARMA, INC. / CIK 0001517681
Captured
2026-09-20T09:14:07.933Z
SEC response SHA-256
4f6eac6bf72e7f988a9a94ea85589b445974414449c4b417540ed20477181487

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001517681.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))